Robert J. Motzer
罗伯特·莫策尔
MD
Jack and Dorothy Byrne Chair in Clinical Oncology; Attending Physician, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer CenterJack and Dorothy Byrne临床肿瘤学冠名讲席；纪念斯隆凯特琳癌症中心泌尿生殖肿瘤科主治医师
👥Biography 个人简介
Robert J. Motzer, MD holds the Jack and Dorothy Byrne Chair in Clinical Oncology and is an Attending Physician in the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. He is widely regarded as one of the most influential figures in the history of renal cell carcinoma treatment, having been the lead investigator in virtually every era-defining clinical trial in metastatic RCC over three decades. He was the principal investigator for CheckMate 214, the landmark phase III trial that established nivolumab combined with ipilimumab as the first dual immunotherapy regimen to demonstrate superior overall survival over sunitinib in intermediate- and poor-risk metastatic clear cell RCC, based on durable complete responses and a long overall survival tail. He also led the sunitinib phase III trial, the AXIS trial of axitinib, and the cabozantinib and lenvatinib combination trials in advanced RCC. Dr. Motzer developed the MSKCC prognostic criteria (Motzer criteria) that preceded the IMDC model, and co-developed the IMDC model itself. He has published over 500 peer-reviewed papers and is the single most cited researcher in the RCC field.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CheckMate 214 — Nivolumab+Ipilimumab Establishes Dual IO as First-Line Standard in Intermediate/Poor-Risk RCC
Led CheckMate 214, the phase III trial demonstrating that nivolumab plus ipilimumab significantly improved overall survival, objective response rate, and complete response rate versus sunitinib in intermediate- and poor-risk metastatic clear cell RCC, leading to FDA approval and establishing dual checkpoint blockade as a first-line option with potential for durable remission.
MSKCC Prognostic Model (Motzer Criteria) for Metastatic RCC
Developed the Memorial Sloan Kettering Cancer Center (MSKCC) prognostic model—incorporating five clinical variables including performance status, hemoglobin, LDH, corrected calcium, and time from diagnosis to systemic therapy—which stratified metastatic RCC patients into favorable, intermediate, and poor risk groups and became the global standard for clinical trial stratification in the cytokine era.
Lenvatinib + Everolimus and Lenvatinib + Pembrolizumab in Advanced RCC
Led phase II and phase III evaluation of lenvatinib-based combinations in metastatic RCC, including the CLEAR/KEYNOTE-581 trial demonstrating superior efficacy of lenvatinib plus pembrolizumab over sunitinib in first-line clear cell RCC, adding another IO+VEGFR option to the treatment landscape.
Cabozantinib in VEGFR-Refractory RCC and Nivolumab+Cabozantinib in First-Line RCC
Led the CheckMate 9ER trial evaluating nivolumab combined with cabozantinib in first-line advanced RCC, demonstrating superior overall survival and PFS over sunitinib, and contributed to the phase III METEOR trial establishing cabozantinib as a second-line standard after prior VEGFR therapy.
Representative Works 代表性著作
Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma (CheckMate 214)
New England Journal of Medicine (2018)
Phase III CheckMate 214 trial establishing nivolumab plus ipilimumab as a first-line standard for intermediate- and poor-risk advanced clear cell RCC, demonstrating superior OS and durable complete responses versus sunitinib.
Prognostic factors for survival in patients with advanced renal-cell carcinoma treated with interferon-alfa
Journal of Clinical Oncology (1999)
Development of the MSKCC (Motzer) prognostic model for metastatic RCC, the first validated risk stratification system and the precursor to the modern IMDC model.
Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma (CLEAR)
New England Journal of Medicine (2021)
Phase III CLEAR trial establishing lenvatinib plus pembrolizumab as a first-line standard for advanced RCC with superior PFS, OS, and ORR versus sunitinib.
Nivolumab plus cabozantinib versus sunitinib in advanced renal-cell carcinoma (CheckMate 9ER)
New England Journal of Medicine (2021)
Phase III CheckMate 9ER trial demonstrating superior PFS, OS, and ORR with nivolumab plus cabozantinib versus sunitinib in first-line advanced clear cell RCC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 罗伯特·莫策尔 的研究动态
Follow Robert J. Motzer's research updates
留下邮箱，当我们发布与 Robert J. Motzer（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment